Best Low Price Stocks To Watch Right Now

Following past boom/bust cycles, the oil business appears to have bottomed in February 2016 at $27 a barrel. The bruising multi-year bust in crude oil prices was the biggest reason for the world stock market sell-off from late 2015 to early 2016 of roughly 15% overall. The cruel irony of ultra-low prices is its disruptive effect on regular exploration activity. A short-term oil market depression in expectations disproportionately slashes oil drilling activity. Oil exploration budgets for 2017 are down 65% from 2014 and the smallest in 12 years, DESPITE a record estimate for global demand next year. In the long-run, oil & gas development and production may fail to keep pace with the steady growth in total demand. Will the 2015-16 “bust” sow the seeds of the next “boom” phase in pricing?

Click to enlarge

Best Low Price Stocks To Watch Right Now: Taiwan Semiconductor Manufacturing Company Ltd.(TSM)

Advisors’ Opinion:

  • [By Ashraf Eassa]

    Contract-chip manufacturing giant Taiwan Semiconductor Manufacturing Company (NYSE:TSM) recently announced its earnings results, provided forward guidance for the current quarter, and provided a lot of insight on the ramp-up of its next-generation chip-manufacturing technology, called 10-nanometers (10nm for short).

  • [By Ashraf Eassa]

    A while back, DigiTimes reported that Taiwan Semiconductor Manufacturing Company (NYSE:TSM), a major contract chip manufacturer, planned to introduce an enhanced variant of its 16nm manufacturing technology dubbed “12nm.”

  • [By Ashraf Eassa]

    As part of this discussion, he took the time to explain how the technology that Intel calls 14 nanometers is more like what its competitors — Samsung (NASDAQOTH:SSNLF) and Taiwan Semiconductor Manufacturing Co.(NYSE:TSM) — call 10 nanometers (smaller is generally believed to be better).

Best Low Price Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

Best Low Price Stocks To Watch Right Now: Vermillion, Inc.(VRML)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

Leave a Reply

Your email address will not be published. Required fields are marked *